POS1214 PATIENT REPORTED OUTCOME FOR PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY

Background Patient-reported outcomes (PRO) measures provide direct and valuable information on treatment efficacy quality of life. However, the commonly-used PRO in Idiopathic inflammatory myopathies (IIM) have several psychometric limitations. The Patient-Reported Outcomes Measurement Information System (PROMIS) is an NIH initiative, with PROs developed validated different medical conditions. Objectives To (1) investigate properties PROMIS physical function-20 (PF-20) a large US-wide IIM population, (2) evaluate feasibility compliance administered local clinic compared to remote patients. Methods “Myositis Patient Centered Tele-Research” (My PACER) multi-center prospective 6-month observational study U.S. subjects, competitively recruited through traditional in-person visits (Center-Based Cohort [CBC]), remotely using smartphone technology, wearable devices, telemedicine principles (Tele-Research [TRC]). Data collection included baseline demographic clinical parameters, other patient self-assessments at 6 monthly visits, including myositis core set (health assessment questionnaire [HAQ-DI], global disease activity), PF-20, functional tests (six-minute walk, timed up-and-go [TUG] sit-to-stand [STS] tests], activity monitor. Physician-reported assessments (manual muscle testing [MMT], physician activity, extra-muscular creatine kinase [CK]) were obtained months. Results 141 patients enrolled (94 TRC/47 CBC). Mean age was 55±13.4 years, female sex 106/141 (75.2%), 113/141 (80.1%) Caucasians, similar demographics between two groups. 116 completed PROMIS-PF form (79 (84%) 37 (78.7%) TRC vs. CBC group) mean 6.6±1.7 6.3±1.5 times per (p=0.33) group, respectively. PF-20 score not associated age, gender or race. There no difference groups (p=0.84). 43.9 ± 9.5 whole cohort, 26/116 (22.4%) t-score lower than 35, indicating severe limitation, which showed strong test-retest reliability high correlation when repeated 1 month (r=0.94,p<0.0001). At baseline, significantly all except CK. In addition, symptoms as well (Table 1), good validity. Finally, absolute changes (between visit) some STS activity. Conclusion demonstrates favorable cohort patients, results traditionally from clinics social media digital health technology. Table 1. Validity. Associations 20 legacy outcome Parameter Coefficient P value CK level (Muscle Enzyme) * -0.0004 0.65 Global Disease Activity* -2.40 <0.001 Muscle weakness -10.14 pain -6.23 Fatigue -8.80 Joint -6.6 0.002 HAQ score* -11.09 Physician Activity -1.89 MMT-8* 0.31 MDAAT -9.31 Myalgia -8.48 Myositis- mild -7.54 Constitutional -2.83 Skeletal -4.64 -2.37 Physical Function Average steps minute 0.73 0.006 Sit-to-stand (average score) 1.21 Timed up go -0.45 *Myositis Core Set Measure REFERENCES: NIL. Acknowledgements: Disclosure Interests Shiri Keret: None declared, Raisa Lomanto Silva: Akanksha Sharma: Tanya Chandra: Siamak Moghadam-Kia: Chester V Oddis: Rohit Aggarwal Consultant of: Mallinckrodt, Octapharma, CSL Behring, Bristol, Myers-Squibb, EMD Serono, Q32, Kezar, Pfizer, AstraZeneca, Alexion, Argenx, Boehringer Ingelheim (BI), Corbus, Janssen, Kyverna, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therapeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, CabalettaBio., Grant/research support from: Bristol (BI)